Anti-Mouse GM-CSF Antibody (MP1-22E9) 

Anti-Mouse GM-CSF Antibody (MP1-22E9) is a rat-derived anti-mouse GM-CSF IgG2a antibody inhibitor. Anti-Mouse GM-CSF Antibody (MP1-22E9) can neutralize GM-CSF. Anti-Mouse GM-CSF Antibody (MP1-22E9) can be used for the researches of cancer, infection inflammation and immunology, such as cholangiocarcinoma and arthritis^{[1][2][3][4][5][6]}.

Rat IgG2a kappa

Rat IgG2a kappa, Isotype Control

Mouse

GM-CSF

Anti-Mouse GM-CSF Antibody (MP1-22E9) (72 h) significantly reduces macrophage viability in bone marrow -derived macrophages^[1].
Anti-Mouse GM-CSF Antibody (MP1-22E9) (10 μg/mL, 30 mins) promotes differentiation and migration in myeloid-derived suppressor cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Mouse GM-CSF Antibody (MP1-22E9) (30 mg/kg, i.p., every 2days for 4 week) inhibits progression of tumor and extended survival in autochthonous intrahepatic cholangiocarcinoma mice models^[1].
Anti-Mouse GM-CSF Antibody (MP1-22E9) (800 μg, i.p., every monday and thursday for 2 weeks) decreases angiogenesis in L2/IKKβca mice^[2].
Anti-Mouse GM-CSF Antibody (MP1-22E9) (250 μg, i.p., at the day before curdlan injection and twice weekly for 7 weeks or 9 days after disease triggering and twice weekly until day 28) inhibits bone marrow myelopoiesis and organ inflammation in spondyloarthritis mice models^[3].
Anti-Mouse GM-CSF Antibody (MP1-22E9) (200 μg, i.p., every 3 days) inhibits antitumor immunity by neutralizing GM-CSF in B16F10-OVA tumor-bearing mice models^[4].
Anti-Mouse GM-CSF Antibody (MP1-22E9) (100 μg, i.p., twice a week) shows anti-tumor effect in HM-1 tumor mice models^[5].
Anti-Mouse GM-CSF Antibody (MP1-22E9) (250 μg, i.p., every other day beginning one day prior to infection for 3 times) shows anti-infection effect in clostridium difficile infected mice models^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

12981  [NCBI]

Q14AD9

in vivo GM-CSF neutralization; in vitro GM-CSF neutralization; Flow cytometry

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

150 kDa

Liquid

Colorless to light yellow

[Anti-Mouse GM-CSF Antibody (MP1-22E9)]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ruffolo LI, et al. GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity. Gut. 2022 Jul;71(7):1386-1398.  [Content Brief]

  [2]. Tétreault MP, et al. Esophageal Expression of Active IκB Kinase-β in Mice Up-Regulates Tumor Necrosis Factor and Granulocyte-Macrophage Colony-Stimulating Factor, Promoting Inflammation and Angiogenesis. Gastroenterology. 2016 Jun;150(7):1609-1619.e11.  [Content Brief]

  [3]. Regan-Komito D, et al. GM-CSF drives dysregulated hematopoietic stem cell activity and pathogenic extramedullary myelopoiesis in experimental spondyloarthritis. Nat Commun. 2020 Jan 9;11(1):155.  [Content Brief]

  [4]. Kim IK, et al. GM-CSF Promotes Antitumor Immunity by Inducing Th9 Cell Responses. Cancer Immunol Res. 2019 Mar;7(3):498-509.  [Content Brief]

  [5]. Horikawa N, et al. Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment. Br J Cancer. 2020 Mar;122(6):778-788.  [Content Brief]

  [6]. McDermott AJ, et al. Role of GM-CSF in the inflammatory cytokine network that regulates neutrophil influx into the colonic mucosa during Clostridium difficile infection in mice. Gut Microbes. 2014 Jul 1;5(4):476-84.  [Content Brief]